Mounjaro vs Ozempic
How tirzepatide and semaglutide actually differ in 2026 — mechanism, head-to-head efficacy, list price, side effects, and how to access each.
Mounjaro (tirzepatide) is a dual GIP and GLP-1 receptor agonist; Ozempic (semaglutide) is GLP-1-only. Both are once-weekly injections FDA-approved for type 2 diabetes. In the head-to-head SURMOUNT-5 trial, tirzepatide drove 20.2% average weight loss versus 13.7% for semaglutide. List prices run about $1,069 (Mounjaro) versus $998 (Ozempic) per month. Prices are estimates to confirm with the pharmacy. This is information, not medical advice.
Last updated: June 2026 • 11 min read
Mounjaro vs Ozempic at a Glance (2026)
| Attribute | Mounjaro (tirzepatide) | Ozempic (semaglutide) |
|---|---|---|
| Active ingredient | Tirzepatide | Semaglutide |
| Drug class / mechanism | Dual GIP + GLP-1 receptor agonist | GLP-1 receptor agonist (single) |
| Maker | Eli Lilly | Novo Nordisk |
| FDA-approved use | Type 2 diabetes (glycemic control) | Type 2 diabetes (glycemic control) |
| Weight-loss brand (same drug) | Zepbound | Wegovy |
| Administration | Once-weekly injection | Once-weekly injection |
| Dose range | 2.5 → 15 mg (2.5-mg steps) | 0.25 → 2 mg |
| Approx. list price (2026) | ~$1,069 / month | ~$998 / month |
List prices are advertised 2026 wholesale figures and change frequently; your actual cost depends on dose, pharmacy, and coverage. Confirm current pricing and savings-card eligibility before filling. For the full picture on how these drugs work for weight loss, see the complete GLP-1 weight-loss guide.
The Core Difference: One Hormone vs Two
The two drugs are not the same molecule, and the difference is mechanistic. Ozempic is semaglutide, a GLP-1 receptor agonist — it mimics a single gut hormone (GLP-1) that slows stomach emptying, blunts appetite, and improves insulin response. Mounjaro is tirzepatide, which Lilly describes as the first and only FDA-approved dual GIP and GLP-1 receptor agonist: a single molecule that activates two incretin pathways instead of one.
That extra GIP activity is the headline distinction. It is also why there is no clean milligram-to-milligram equivalence between the two — the doses are not interchangeable, and a switch is a clinical decision, not a conversion you do yourself. Both drugs are once-weekly subcutaneous injections: Ozempic titrates 0.25 → 0.5 → 1 → 2 mg, while Mounjaro starts at 2.5 mg and steps up by 2.5 mg toward a 15 mg maximum.
Head-to-Head Efficacy: What the Trials Show
Two head-to-head trials — one for diabetes, one for weight — give an unusually direct comparison.
For type 2 diabetes (SURPASS-2). This NEJM-published trial randomized 1,879 adults with type 2 diabetes to tirzepatide (5, 10, or 15 mg) or semaglutide 1 mg. All three tirzepatide doses were statistically superior to semaglutide for A1C reduction, and the 15 mg dose produced nearly double the weight loss of semaglutide 1 mg. Note this compared the 1 mg diabetes dose of semaglutide, not the higher weight-loss dose.
For weight (SURMOUNT-5). This 72-week NEJM-published trial enrolled 751 adults with obesity (without type 2 diabetes) and compared the two drugs head-to-head. Tirzepatide produced an average 20.2% body-weight reduction versus 13.7% for semaglutide — about 47% greater relative weight loss — and was superior on all five key secondary endpoints. One important framing: SURMOUNT-5 used the weight-loss-approved brands Zepbound (tirzepatide) and Wegovy (semaglutide), not Mounjaro and Ozempic.
The names matter. Mounjaro and Ozempic are the diabetes brands; Zepbound and Wegovy are the same active drugs branded for weight management. The trial efficacy figures above come from the weight-loss formulations. Using Mounjaro or Ozempic itself for weight loss is off-label — a clinician decision, not a default.
Cost: What You Actually Pay
On paper the two are close. As of early 2026, Eli Lilly’s wholesale acquisition cost for Mounjaro is about $1,069 per 28-day supply, and Ozempic’s list price is about $998 per month. Almost no one pays the full list price, though — what you actually pay depends on three things:
- Insurance coverage. Both are commonly covered for type 2 diabetes; coverage for off-label weight use is far less reliable. Your formulary and prior-auth rules drive the real number.
- Manufacturer savings cards. For eligible commercially insured patients, the Mounjaro savings card can bring cost down to as little as $25 per fill (with a per-fill cap). Eligibility excludes government insurance.
- Self-pay routes for the weight-loss brands. Lilly’s direct self-pay program lists single-dose tirzepatide (Zepbound) vials starting around $349 per month — relevant if your goal is weight management rather than diabetes.
Bottom line: the list-price gap between Mounjaro and Ozempic is small relative to the swing your coverage and savings programs create. Get a real quote for your specific dose and plan rather than budgeting off the list price.
Side Effects: Largely Shared, With Nuance
The two drugs share most of their safety profile. For both, the most common side effects are gastrointestinal — nausea, diarrhea, vomiting, constipation, and abdominal pain — and they typically show up during dose increases and ease as the body adjusts. For Ozempic, published trial figures put nausea around 15.8% at the 0.5 mg dose and 20.3% at 1 mg.
Both also carry the FDA’s boxed warning — its highest-level warning — for a risk of thyroid C-cell tumors, based on rodent studies. Both list rarer but serious risks including pancreatitis and gallbladder problems. One head-to-head data point: in SURMOUNT-5, GI side effects led to stopping treatment more often with semaglutide (5.6%) than tirzepatide (2.7%).
Who should not take these: the boxed warning means these drugs are contraindicated for people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. This is general information — your eligibility, risks, and the right drug are decisions for a licensed clinician.
Which One Is Right for You?
There is no single "winner" — the right drug depends on your goal, your tolerance, and what your clinician and coverage support. A few honest framings:
Mounjaro / tirzepatide may fit if
- ✓Trial data showed larger average weight loss and A1C reduction head-to-head
- ✓You and your clinician want the dual GIP + GLP-1 mechanism
- ✓You have access and tolerate the titration to higher doses
Ozempic / semaglutide may fit if
- ✓It is the option your insurance covers or your clinician prefers
- ✓It has the longer real-world track record as a GLP-1 single agonist
- ✓You are already established on it and tolerating it well
Before you start or switch, work through these with your prescriber:
- Is the prescription for diabetes (on-label) or weight management (off-label here)?
- What does your plan actually cover, and are you savings-card eligible?
- How will the dose be titrated, and what GI side effects should you expect early?
- Do you have any thyroid or pancreatitis history that changes the risk calculus?
Frequently Asked Questions
Is Mounjaro or Ozempic better for weight loss?▼
In the head-to-head SURMOUNT-5 trial, tirzepatide (the drug in Mounjaro) produced an average 20.2% body-weight reduction versus 13.7% for semaglutide (the drug in Ozempic) over 72 weeks — about 47% greater relative weight loss. Two caveats matter: that trial used the weight-loss formulations Zepbound and Wegovy, not Mounjaro and Ozempic, and neither Mounjaro nor Ozempic is FDA-approved for weight loss. Discuss which medication fits your situation with a licensed clinician.
What is the difference between Mounjaro and Ozempic?▼
Mounjaro is tirzepatide, a dual GIP and GLP-1 receptor agonist — it activates two incretin pathways. Ozempic is semaglutide, a GLP-1-only receptor agonist. Both are once-weekly subcutaneous injections FDA-approved for type 2 diabetes, made by Eli Lilly (Mounjaro) and Novo Nordisk (Ozempic). The extra GIP activity in tirzepatide is the main mechanistic difference and is why there is no exact mg-to-mg dose equivalence between them.
How much do Mounjaro and Ozempic cost without insurance in 2026?▼
As of early 2026, Mounjaro’s list (wholesale acquisition) price is about $1,069 per month and Ozempic’s is about $998 per month. Manufacturer savings cards can lower the cost to as little as $25 per fill for eligible commercially insured patients, and self-pay programs exist for the sister weight-loss brands. These are advertised list prices that change and vary by pharmacy, dose, and coverage — confirm the current cash price with the pharmacy and check savings-card eligibility.
Are Mounjaro and Ozempic approved for weight loss?▼
No. Mounjaro and Ozempic are both FDA-approved only to improve blood sugar in adults with type 2 diabetes. The same active ingredients are FDA-approved for chronic weight management under different brand names: Zepbound (tirzepatide) and Wegovy (semaglutide). Prescribing Mounjaro or Ozempic specifically for weight loss is off-label. Talk to a clinician about which approved option is appropriate for you.
Do Mounjaro and Ozempic have the same side effects?▼
They share a similar profile. The most common side effects of both are gastrointestinal — nausea, diarrhea, vomiting, constipation, and abdominal pain — typically during dose increases. Both carry the FDA’s boxed warning for a risk of thyroid C-cell tumors (based on rodent studies), and both list rarer serious risks such as pancreatitis and gallbladder problems. In the SURMOUNT-5 trial, GI side effects led to discontinuation more often with semaglutide (5.6%) than tirzepatide (2.7%). This is information, not medical advice.
Can you switch from Ozempic to Mounjaro?▼
Switching between the two is done only under a clinician’s direction, because there is no exact mg-to-mg equivalence — tirzepatide’s added GIP activity changes both response and tolerability. A typical approach restarts at a lower introductory tirzepatide dose (2.5 mg weekly) and titrates up rather than matching the prior semaglutide milligrams. Never change or switch a prescription on your own; ask the prescribing clinician how to transition safely.
Compare GLP-1 Weight-Loss Options
See cash-pay GLP-1 programs, telehealth providers, and what they cost — all in one place.
Explore Weight-Loss Options →Related Guides
Sources
- • Eli Lilly — Zepbound superior to Wegovy in SURMOUNT-5 head-to-head (20.2% vs 13.7%)
- • American College of Cardiology — SURMOUNT-5 journal scan
- • Eli Lilly — SURPASS-2 results in NEJM (tirzepatide vs semaglutide, type 2 diabetes)
- • Eli Lilly — FDA approves Mounjaro (first GIP and GLP-1 receptor agonist)
- • Mounjaro (tirzepatide) FDA Prescribing Information
- • Drugwatch — Ozempic side effects & FDA warnings
Medical disclaimer: This page is general information, not medical advice. Listings are aggregated from public sources and prices are estimates that may be out of date — confirm current pricing, services, and provider credentials directly with each clinic. Talk to a licensed clinician before starting any medication or treatment.
Affiliate disclosure: VitalityScout may earn a commission from some links, at no additional cost to you. This never affects which providers we list or how we describe them.
Weighing GLP-1 Options?
Get our plain-English breakdown of GLP-1 medications, costs, and how to access them — without the hype.
No spam, unsubscribe anytime.